Click here to check out calendar of events for this month.
CMSC News:
For a complete listing of CMSC News, please click here.
May 1, 2012 - Vicente Rocafuerte Condecoration bestowed on Dr. Donald Silberberg, MD 
April 26, 2012 - Updates from 64th Annual Meeting of the American Academy of Neurology
April 20, 2012 - Novartis announces update to Gilenya US Prescribing Information following FDA review
February 8, 2012 - Announcing upcoming event: Symposium and Dinner to Honor Dr. Robert P. Lisak on May 18, 2012 in Detroit, MI, USA
December 20, 2011 - Important information from the Annals of Neurology
CMSC Community News:
For a complete listing of CMSC Community News, please click here.
CMSC INForMS (Industry News for MS):
For a complete listing of CMSC Industry News for MS, please click here.
- May 14, 2012 - New Avonex Dosing Innovations for People with Multiple Sclerosis Now Available in US
- May 14, 2012 - FDA Drug Safety Communication: Revised Recommendations for Cardiovascular Monitoring and Use of Multiple Sclerosis Drug Gilenya (Fingolimod)
- April 29, 2012 - Tysabri Seems OK for Expectant Mothers with MS
- April 27, 2012 - Two MS Drugs No Better than One
- April 27, 2012 - Menopause Impact Negligible in MS
- April 26, 2012 - More Negative Results for Vein Blockage in MS
- April 26, 2012 - Slow MS Progress Most Likely if Diagnosed Young
- April 26, 2012 - EMD Serono to Present New Data on Multiple Sclerosis at the American Academy of Neurology's 64th Annual Meeting
- April 26, 2012 - Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned to Teva's COPAXONE®
- April 25, 2012 - Glatiramer-IFN Combo in MS a Toss-Up
- April 25, 2012 - Patients Drop MS Drug, Face Relapse Risk
- April 25, 2012 - EMD Serono, Inc. Founding Donor of Newly Launched MGH Multiple Sclerosis Discovery Forum
- April 25, 2012 - Research on Gene Therapy Published by Investigators at Hamamatsu University
- April 25, 2012 - Acorda Therapeutics Presents AMPYRA Long-Term Safety and Efficacy Data at 64th American Academy of Neurology Annual Meeting
- April 25, 2012 - NICE recommends first pill treatment for some people with MS
- April 24, 2012 - Oral Steroids Effective in MS
- April 24, 2012 - Positive Results from Phase 3 CONFIRM Clinical Trial Show Efficacy and Safety of Oral BG-12 in Multiple Sclerosis
- April 24, 2012 - Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada™* (Alemtuzumab) Compared With Rebif® in Phase lll Trial
- April 23, 2012 - New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
- April 20, 2012 - New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases
- April 20, 2012 - Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll Trials
- April 20, 2012 - Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
- April 19, 2012 - Study: Use of Drug Following First Sign of Possible MS Reduces Likelihood of Progression to MS
- April 18, 2012 - Teva Announces New Data on Central Nervous System Products to Be Presented at 2012 American Academy of Neurology Annual Meeting
- April 17, 2012 - Novel MS Pill Passes Early Test
- April 17, 2012 - Accelerated Cure Project for Multiple Sclerosis (ACP) and MassGeneral Institute for Neurodegenerative Disease (MIND) Launch Multiple Sclerosis Discovery Forum
- April 11, 2012 - FAMPYRA™, the First Oral Treatment for the Improvement of Walking in MS, is Now Available in Canada
- April 2, 2012 - Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampyra (Dalfampridine) of Walking Problems in Patients with Multiple Sclerosis
- March 22, 2012 - Update on Gilenya
- March 16, 2012 - Additional Evidence Means First Pill for MS Could Soon be Recommended for Some Patients
- March 15, 2012 - Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients
- March 13, 2012 - Multiple Sclerosis Expert Dr. Alfred Sandrock from Biogen Idec Joins the Myelin Repair Foundation's Clinical Advisory Board
- March 12, 2012 - BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis
- March 7, 2012 - Myelin Repair Foundation Research Fosters a Clinical Trial for Multiple Sclerosis
- March 5, 2012 - Transparency Life Sciences Obtains Exclusive Option from Stanford University for use of Lisinopril in Multiple Sclerosis
- March 5, 2012 - Concert Pharmaceuticals and Fast Forward Announce Collaboration to Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis
- March 1, 2012 - Almirall supports European post-graduate clinical research into MS spasticity with two annual grants
- February 29, 2012 - Biogen Idec Applies to FDA for Approval of BG-12 to Treat MS
- February 28, 2012 - FDA Approves Avonex Pen and Dose Titration Regimen
- February 27, 2012 - Multiple Sclerosis: Damaged Myelin Not the Trigger
- February 23, 2012 - Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
- February 16, 2012 - Scripps Research Scientists Create New Molecular Map to Guide Development of New Treatments for Multiple Sclerosis and Other Diseases
- February 8, 2012 - The Myelin Repair Foundation and ENDECE Neural Form Collaboration to Develop Myelin Regenerative Compounds for Multiple Sclerosis (MS) Treatment
- February 7, 2012 - Important News from Bayer regarding Gadavist™
- February 6, 2012 - Findings from Catholic University Provide New Insights into Multiple Sclerosis
- January 27, 2012 - FDA Changes Tysabri Label to Include Anti-JC Virus Antibody Status as a
PML Risk Factor
- January 26, 2012 - ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
- January 25, 2012 - Merck Serono Receives European Approval to Expand Use of Rebif® in Patients with Early Multiple Sclerosis
- January 25, 2012 - EMA Seeks Industry Comments On IFN-Beta Draft Guideline
- January 23, 2012 - MS LifeLines Earns J.D. Power and Associates Call Center Certification for Customer Service Excellence in Providing Support Services to the MS Community
- January 20, 2012 - European Medicines Agency Commences Safety Review of Gilenya
- January 19, 2012 - Adeona Announces Initiation of Phase II Clinical Trial of Trimesta for Cognitive Dysfunction in Multiple Sclerosis
- January 3, 2012 - Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE®
- December 21, 2011 - MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis
- December 20, 2011 - FDA Drug Safety Communication: Safety review of a reported death after the first dose of Multiple Sclerosis drug Gilenya (fingolimod)
- December 20, 2011 - Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis
- December 12, 2011 - Findings could change way MS is diagnosed, treated
- December 8, 2011 - From the Front Lines: MS Research to Follow in 2012
- December 7, 2011 - From the Outside In: Mayo Clinic Collaboration Finds Multiple Sclerosis Often Starts in Brain's Outer Layers
- December 3, 2011 - World First in MS Fight
- November 18, 2011 - Merck Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif® to Treat Patients With Early Signs of Multiple Sclerosis
- November 14, 2011 - Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADATM*) in Multiple Sclerosis
- November 9, 2011 - Nuron Biotech Initiates Phase 3 Study of Proprietary Recombinant Human Interferon Beta-1b NU100 in Relapsing Remitting Multiple Sclerosis
- November 3, 2011 - Avanir Pharmaceuticals Announces Enrollment of First Patient in PRIME Study of AVP-923 in Central Neuropathic Pain in Multiple Sclerosis
- November 2, 2011 - Geron Announces Presentation At ECTRIMS/ACTRIMS
- November 2, 2011 - Data on Relapsing-Remitting Multiple Sclerosis Detailed by Researchers at Novartis Pharmaceuticals
|
